1. WORK Medical received manufacturing approval for AI blood cell analyzer. 2. The device enhances efficiency in blood morphology testing. 3. CEO optimistic about product line's growth and revenue potential. 4. Approval positions WORK Medical for increased market competitiveness. 5. Upcoming manufacturing to commence in first half of 2026.
FAQ
Why Bullish?
The approval for the AI analyzer can significantly drive WOK’s market share, similar to previous tech implementations enhancing operational efficiency in medical firms, which often lead to positive price movement.
How important is it?
Approval directly influences WOK's product pipeline, enhances growth narrative, and suggests potential market leadership.
Why Long Term?
The anticipated manufacturing rollout in 2026 positions WOK for sustained market growth, akin to past successes in prolonged AI adoption cycles in healthcare.
WORK Medical Technology Group LTD Secures Manufacturing Approval for AI-Powered Blood Cell Analyzer
Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK), a leading supplier of medical devices in China, announced significant progress in its operations. The Company, through its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries, has successfully received manufacturing approval from the Hunan Provincial Medical Products Administration. This approval is for the Class II medical device, the Artificial Intelligence (AI)-Automated Human Blood Cell Morphology Analyzer, marking a key milestone in WORK Medical's growth strategy.
Details of the AI-Automated Analyzer
The innovative analyzer includes a main unit and integrated analysis software. Key components of the device consist of:
- Optical imaging system
- Sample-handling module
- Barcode scanner
- Automatic oil-immersion unit
- Control board
- Protective housing
This sophisticated device performs white blood cell differential counts on human blood smears and quantifies the morphological parameters of red blood cells and platelets. By enabling clinicians to effectively conduct cell morphology screening, the analyzer is set to enhance diagnostic efficiency.
Impact of AI Technology on Medical Testing
Fueled by advanced AI automation, the morphology analyzer utilizes high-speed digital imaging and deep-learning algorithms. It provides a fully automated workflow that identifies, pre-classifies, and describes the morphology of hematological components in peripheral blood smears. Manufacturing for this device is expected to commence in the first half of 2026, aimed at increasing diagnostic accuracy while reducing manual workloads and operational costs.
Mr. Shuang Wu, the CEO and Chairman of WORK Medical, expressed his optimism, stating: “This new analyzer integrates cutting-edge AI technology into traditional medical testing, improving consistency, efficiency, and accuracy while minimizing manual intervention and associated costs. We are optimistic about this product line’s growth and its revenue potential for the Company.”
About WORK Medical Technology Group LTD
WORK Medical Technology Group LTD is a prominent developer and manufacturer of Class I and II medical devices, selling numerous disposable medical devices through its subsidiaries in China. The Company boasts a diverse product portfolio featuring 21 medical products including specialized masks and consumables. Currently, their products are available in 34 provincial-level regions across China, with international distribution in over 30 countries.
The Company has obtained several quality-related manufacturing certifications and has registered 17 products with the U.S. Food and Drug Administration (FDA), facilitating their entrance into the U.S. market.
For further information, visit the Company’s official website: WORK Medical Technology Group.
Important Considerations and Forward-Looking Statements
This announcement contains forward-looking statements as per the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of terms such as “anticipates,” “believes,” “expects,” “potential,” and other similar expressions. It is important for investors to note that these forward-looking statements are contingent upon numerous factors and entail risks that may lead to actual results differing significantly from the anticipated outcomes.
Contact Information
For investor inquiries, please reach out to:
- WORK Medical Technology Group LTD
Investor Relations Department
Email: ir@workmedtech.com - Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com